Skip to main content
Journal of Patient-Reported Outcomes

Table 7 Known-groups comparisons

From: Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease

 

4FS

Item 1

Tiredness at rest

Item 2

Tiredness during activities

Item 3

Muscle weakness at rest

Item 4

Muscle weakness during activities

Item 5

Balance problems

Item 6

Vision problems

Item 7

Abdominal discomfort

Item 8

Muscle pain

Item 9

Numbness

Item 10

Headache

PhGA scores: Fair/Poor versus Excellent/Very Good

 Poor PhGA (n = 7–14)*

11.2

2.8

2.9

2.6

3.0

2.7

2.1

2.0

2.4

2.0

1.6

 Good PhGA (n = 2–6)*

8.0

2.0

2.1

1.8

2.1

1.8

2.0

1.8

2.1

1.4

1.8

 Difference†

3.2

0.8

0.8

0.8

0.9

0.9

0.1

0.2

0.4

0.6

-0.2

PGA scores: Fair/Poor versus Excellent/Very Good

 Poor PGA (n = 14–20)*

11.4

2.8

3.0

2.59

3.0

2.7

2.3

2.0

2.5

1.9

1.7

 Good PGA (n = 1–5)*

8.1

2.1

2.2

1.76

2.1

1.8

1.9

1.3

1.6

1.5

1.2

 Difference†

3.2

0.7

0.8

0.83

0.9

0.8

0.4

0.7

0.9

0.4

0.5

6MWT: < 400 m versus  ≥ 400 m

 < 400 m 6MWT group (n = 12–17)*

10.9

2.7

2.8

2.5

2.9

2.6

2.3

1.8

2.3

1.9

1.5

 ≥ 400 m 6MWT group (n = 12–17)*

10.4

2.6

2.8

2.3

2.7

2.3

2.1

2.0

2.3

1.7

1.7

 Difference†

0.5

0.0

0.1

0.2

0.2

0.3

0.2

-0.1

0.0

0.3

-0.1

  1. 4FS = Fatigue 4 Scale; 6MWT = six-minute walk test; PGA = Patient Global Assessment; PhGA = Physician Global Assessment; SD = standard deviation
  2. *Average
  3. †Mean group difference averaged over time at examined visits
Back to article page